Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych MEQs / SAQsSpecialty psychiatry — sleep medicine interface

Psych MEQs / SAQs · Specialty psychiatry — sleep medicine interface

Chronic insomnia disorder with residual depression and long-term Z-drug use (MEQ)

FRANZCP-style MEQ on insomnia disorder: CBT-I first-line, Z-drug dependence, OSA screen, occupational sleepiness, depression bidirectional risk. FRANZCP-primary, globally tagged.

20 marks20 min
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 46-year-old woman with recurrent MDD reports 5 years of sleep-onset and maintenance insomnia (≥4 nights/week), ISI in the moderate–severe range, and daytime fatigue without true sleepiness. She drinks one to two glasses of wine most nights 'to switch off,' has used zopiclone most nights for 20 months, and has residual PHQ-9 of 13 after two antidepressant trials. BMI 33 kg/m²; partner reports loud snoring. She drives and had one near-miss after nodding at traffic lights. (i) Formulate diagnoses and key differentials. (ii) Outline assessment and investigations. (iii) Propose stepped non-drug and drug management including CBT-I and hypnotic deprescribing. (iv) Address OSA and occupational risk. (v) Link insomnia to depression and suicide risk with evidence. (20 marks)

Model answer

Reveal model answer

(i) Formulation. Chronic insomnia disorder (onset and maintenance, multi-year course, frequency, daytime impairment) comorbid with residual MDD. Maintaining factors: alcohol (shortens latency, fragments architecture), long-term zopiclone with tolerance/dependence pattern, possible OSA (BMI, snoring), and likely Spielman perpetuating behaviours (extended time in bed, sleep effort). Differentials: OSA vs pure psychiatric insomnia, circadian delay less likely from stem, substance-related sleep disruption, medical causes not yet excluded, residual depression driving middle insomnia. Treat insomnia as a disorder even when comorbid.[1][6]

(ii) Assessment/investigations. Structured sleep history and 1–2 week diary; substances; suicide risk; driving risk (near-miss is a red flag). Partner history for apnoeas. ISI for severity/response; ESS if sleepiness/driving is the issue. STOP-BANG-type OSA screen. Review medications and OTCs. Consider sleep study given OSA probability; do not delay CBT-I solely for PSG waitlists. Baseline mood scales; medical labs as indicated (TFT, FBC, glucose).[1][2]

(iii) Stepped plan. Psychoeducation; stop alcohol as hypnotic. CBT-I first-line — stimulus control, sleep restriction with occupational safety planning, cognitive therapy, relaxation, education; face-to-face or digital per access.[1][2][3][6] Optimise depression treatment in parallel (not instead of CBT-I). Hypnotic deprescribing: shared plan to taper zopiclone, avoid escalation, do not replace with open-ended quetiapine for primary insomnia. Short-term bridge only if needed during CBT-I with exit criteria. Sedating antidepressant only if depression warrants, knowing hangover/weight/OSA risks. Morin-type teaching: meds may help short-term; CBT-I durability is superior long-term.[1][8]

(iv) OSA and work. Refer sleep medicine; weight management; alcohol reduction. Pending assessment, discuss temporary work/driving safety after near-miss, OHS liaison as appropriate, jurisdiction fitness-to-drive principles. CPAP if moderate–severe OSA confirmed — support adherence and mood in parallel.[6]

(v) Depression/suicide evidence. Longitudinal meta-analysis shows insomnia predicts incident depression; sleep disturbance associates with suicidal ideation/attempt/death — document SI carefully and treat sleep as part of risk reduction, not optional comfort care.[4][5]

Common errors

  • Only increasing zopiclone dose.
  • Ignoring OSA and alcohol.
  • Claiming CBT-I is optional lifestyle advice or “just hygiene.”
  • Discharging without occupational near-miss plan.
  • Treating insomnia as purely secondary and waiting for full mood remittance before any sleep treatment. [1][2][5]

Examiner notes

Award marks for simultaneous CBT-I + depression optimisation + OSA pathway + deprescribing + risk. Full marks require evidence-linked first-line CBT-I (ACP/AASM/Europe) and suicide/depression bidirectionality. [1][2][4]

References

  1. [1]Qaseem A, Kansagara D, Forciea MA, et al. Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians Ann Intern Med, 2016.PMID 27136449
  2. [2]Edinger JD, Arnedt JT, Bertisch SM, et al. Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline J Clin Sleep Med, 2021.PMID 33164742
  3. [3]Trauer JM, Qian MY, Doyle JS, et al. Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis Ann Intern Med, 2015.PMID 26054060
  4. [4]Baglioni C, Battagliese G, Feige B, et al. Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies J Affect Disord, 2011.PMID 21300408
  5. [5]Pigeon WR, Pinquart M, Conner K Meta-analysis of sleep disturbance and suicidal thoughts and behaviors J Clin Psychiatry, 2012.PMID 23059158
  6. [6]Riemann D, Baglioni C, Bassetti C, et al. European guideline for the diagnosis and treatment of insomnia J Sleep Res, 2017.PMID 28875581
  7. [7]Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits BMJ, 2005.PMID 16284208
  8. [8]Morin CM, Vallieres A, Guay B, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial JAMA, 2009.PMID 19454639